Acadia Pharmaceuticals buy JPMorgan Chase & Co.
Start price
25.03.24
/
50%
€16.50
Target price
25.03.25
€23.06
Performance (%)
-11.39%
Price
05.09.24
€14.62
Summary
This prediction is currently active. The price of Acadia Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -11.39%. This prediction currently runs until 25.03.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Acadia Pharmaceuticals | - | - |
iShares Core DAX® | 2.275% | 4.627% |
iShares Nasdaq 100 | 6.015% | 2.007% |
iShares Nikkei 225® | 4.456% | 3.598% |
iShares S&P 500 | 4.061% | 2.876% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat